Multiple Myeloma: Most Common End-Organ Damage and Management

Author： Hussein Mohamad A.  

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.5, Iss.2, 2007-02, pp. : 170-178

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Breakthroughs in the Management of Multiple Myeloma

By Heffner Jr L.T.   Lonial S.  

Drugs, Vol. 63, Iss. 16, 2003-01 ,pp. : 1621-1636

Adis International

Access to resources Recommend Favorite

Current Trends in Multiple Myeloma Management

By Redzepovic J   Weinmann G   Ott I   Gust R  

The Journal of International Medical Research, Vol. 36, Iss. 3, 2008-05 ,pp. : 371-386

Field House Publishing

Access to resources Recommend Favorite

Management of the Older Patient with Multiple Myeloma

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 34, Iss. 2, 2004-06 ,pp. : 142-146

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pro-Inflammatory Role of Platelets in Hypertension-Mediated End-Organ Damage: Editorial to: “Inhibition of Platelet Activation by Clopidogrel Prevents Hypertension-Induced Cardiac Inflammation and Fibrosis” by L.-X. Jia et al.

By Du Xiao-Jun   Kiriazis Helen  

Cardiovascular Drugs and Therapy, Vol. 27, Iss. 6, 2013-12 ,pp. : 485-487

Springer Publishing Company

Access to resources Recommend Favorite

Thalidomide - most significant drug in decades for multiple myeloma?

By  

Inpharma, Vol. 1, Iss. 1225, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite